December 1, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tamika Sheppard
| Re: | Cartesian Therapeutics, Inc. |
Registration Statement Filed on Form S-3, as amended on December 1, 2023 (the “Registration Statement”)
File No. 333-275171
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date for the above-referenced Registration Statement be accelerated to 5:00 p.m., Eastern Time, on December 1, 2023 or as soon as practicable thereafter.
Please contact Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 or brosenzweig@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Rosenzweig by telephone when this request for acceleration has been granted.
| Respectfully, | ||
| Cartesian Therapeutics, Inc. | ||
| By: | /s/ Carsten Brunn, Ph.D. | |
| Name: | Carsten Brunn, Ph.D. | |
| Title: | President and Chief Executive Officer | |
| cc: | Brian K. Rosenzweig, Covington & Burling LLP |